Drug Manufacturers - General

The group's average sentiment score rose from 6.89 to 7.44, as guidance raises outnumbered cuts across the eight large-cap anchors. Bristol Myers Squibb (BMY) drove the shift, climbing from 4 to 8 after total revenue of approximately $13 billion (up 5.74%) and a growth portfolio up 14% to $7.6 billion let management raise full-year 2026 revenue and adjusted EPS guidance; Eliquis revenue of approximately $4.5 billion, up 21%, offset continued legacy generic erosion. Amgen (AMGN) edged from 8 to 9 on total revenues above $10 billion (up 10%), with its six key growth drivers up 26% to nearly 70% of product sales and full-year guidance raised to revenue of $38.2 billion to $39.4 billion. Pfizer (PFE) improved from 5 to 6 on Q2 revenue of $15 billion (up 1% operationally, about 5% excluding COVID) and a full-year revenue raise to $60.5 billion to $62.5 billion, even as a $4.3 billion noncash impairment produced a reported loss per share of negative $0.04.